Peptide Reports

SS-31

Community Protocol

SS-31

Preparation examples, syringe conversion, community-reported patterns and important limitations.

Educational and calculation-reference material only. Community reports are uncontrolled anecdotes and do not replace professional medical guidance, product labeling, or individualized clinical monitoring.

Scope

Preparation examples, syringe conversion, community-reported patterns and important limitations.

Available strengths: 10 MG and 50 MG

Preparation Examples

These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.

SetupDiluentConcentrationUnit conversion
10 MG vial – 2 mL exampleAdd 2 mL bacteriostatic water5 mg/mLEach U-100 unit = 50 mcg
50 MG vial – 2 mL exampleAdd 2 mL bacteriostatic water25 mg/mLEach U-100 unit = 250 mcg

Syringe Conversion

Reported amount10 MG setup50 MG setup
1 mg20 units4 units
2.5 mg50 units10 units
5 mg100 units20 units
10 mg200 units40 units

Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.

Community-Reported Patterns

Recurring reportFrequency seenContext in reports
1-2.5 mgOnce dailyLower-start reports
5 mgOnce dailyMost recurring amount
10 mgOnce daily in some reportsHigher experimental use

Observations

  • Community discussions most often centered on mitochondrial function, energy, endurance and recovery goals.
  • The amount, frequency, route and cycle length varied substantially between reports.
  • Reported outcomes were commonly confounded by diet, training, other products or existing treatment.

Caveats

  • Elamipretide/SS-31 remains investigational for many uses; human trial formulations do not validate unregulated products.
  • Community reports are uncontrolled anecdotes and do not establish an appropriate dose, safety, product identity, purity or efficacy.

Sources

  1. Community search: SS-31
  2. PubMed literature search: SS-31